awmsg logo



pegvisomant (Somavert®)


Reference No. 3545


Appraisal information

pegvisomant (Somavert®) 10 mg powder and solvent for solution for injection
pegvisomant (Somavert®) 15 mg powder and solvent for solution for injection
pegvisomant (Somavert®) 20 mg powder and solvent for solution for injection
pegvisomant (Somavert®) 25 mg powder and solvent for solution for injection
pegvisomant (Somavert®) 30 mg powder and solvent for solution for injection


Company: Pfizer Ltd
BNF category: Endocrine system
NMG meeting date: 04/10/2017
AWMSG meeting date: 08/11/2017
   
   
Submission Type: Resubmission
Status: In progress
Advice No: Not available
Ministerial ratification: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

Indication

Treatment of patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF-I concentrations or was not tolerated
Preliminary Appraisal Recommendation (PAR)
Download
Company Response to the Preliminary Appraisal Recommendation (CR PAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download